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 Complex regional pain syndrome (CRPS) remains a troubling and often refractory pain condition that typically develops following either injury to a peripheral nerve (type II) or following trauma without obvious peripheral nerve damage (type I).   It presents with a characteristic constellation of sensory, motor, autonomic and vascular signs within which pain is the central feature.  Its aetiology is uncertain [1] and there is an ongoing debate about whether it is primarily a neuropathic or an inflammatory/auto-immune condition [2]. The existing data from treatment trials conventional analgesics, anti-neuropathic pain medications or nerve blocks have been largely disappointing [3, 4] and much of the emphasis in treatment is on functional rehabilitation (see the recent Royal College of Physicians treatment guidelines [5]).  The limitations of existing treatments means that a substantial cohort of CRPS patients (~15,000 new cases per year in the UK based on the incidence figures of de Mos, de Bruijn [6]) is left with refractory, long-term severe pain causing significant disability.  Consequently there is a need to develop innovative treatment approaches such as graded motor imagery, mirror visual feedback, spinal cord stimulation and trans-cranial magnetic stimulation all of which have shown some utility in clinical trials.  Set within this context the review of Niesters et al within this 
Journal is timely, and articulates the arguments for a role of prolonged ketamine infusion in the management of neuropathic pain and specifically for CRPS. 
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delirium was employed in human studies [14].  The recognition of its neuroprotective action led industry to use it as a template to develop other non-competitive NMDA antagonists to treat the excitotoxicity of stroke, head injury and also chronic neurodegenerative conditions [15].   Although animal studies with pre-emptive administration of these NMDA antagonists supported a neuroprotective action, the subsequent clinical studies have failed to identify a significant benefit in most trials.   Concerns have also arisen over potential neurotoxic actions of ketamine seen in some animal studies.  Nonetheless a similar rationale for the use of memantine (another non-competitive NMDA antagonist) in Alzheimer’s disease has seen the drug licenced for clinical use as it can modify the progression of dementia [16]. Most recently ketamine has attracted attention because it can produce an improvement in depressive symptoms in man after acute administration [17]. These antidepressant actions are causing a stir in the field because of the rapid onset of therapeutic effect (unique amongst the currently available medications) which may enable its use as an acute treatment of severe depression.  Reverse translational studies in animals have suggested that this beneficial effect is the product of rapid synapse formation (within hours) within the cortex - reversing the loss in synapse numbers seen in depression [18].  However, it is thought that ketamine is unlikely to be a suitable therapeutic agent in the longer-term treatment of depression because of its challenging pharmacokinetics and psychotomimetic side effects.  Hence the search is currently underway for a better-tolerated NMDA antagonist that might be as efficacious for long term administration in depression [19].  
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have yet to yield a convincing alternative therapy.  A recent meta-analysis of therapeutics for neuropathic pain did not find sufficient evidence to support a role for ketamine or the other NMDA antagonists [24]. 
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